• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Kosasa Thomas bought $749,999 worth of shares (876,136 units at $0.86), increasing direct ownership by 6% to 16,661,327 units (SEC Form 4)

    4/24/26 8:40:19 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ONMD alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Kosasa Thomas

    (Last)(First)(Middle)
    6385 OLD SHADY OAK ROAD, SUITE 250

    (Street)
    EDEN PRAIRIE MINNESOTA 55344

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    OneMedNet Corp [ ONMD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirectorX10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    02/06/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock02/06/2026P(1)595,238A$0.84(2)16,380,429D
    Common Stock04/23/2026P(3)280,898A$0.89(2)16,661,327D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. On February 6, 2026, the issuer entered into a subscription agreement with the reporting person for a $500,000 investment in the issuer.
    2. The shares were valued at the volume-weighted average price for the 10 trading days immediately prior to the applicable purchase date.
    3. On April 23, 2026, the issuer entered into a subscription agreement with the reporting person for a $250,000 investment in the issuer.
    /s/ Robert Golden, Attorney-in-Fact04/24/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $ONMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Yu Jeffrey was granted 219,429 shares and bought $750,000 worth of shares (903,614 units at $0.83), increasing direct ownership by 15% to 8,449,266 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    4/24/26 8:40:21 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Kosasa Thomas bought $749,999 worth of shares (876,136 units at $0.86), increasing direct ownership by 6% to 16,661,327 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    4/24/26 8:40:19 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Executive Officer Green Aaron sold $218,625 worth of shares (126,322 units at $1.73), decreasing direct ownership by 7% to 1,804,103 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    12/23/25 8:00:03 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Yu Jeffrey was granted 219,429 shares and bought $750,000 worth of shares (903,614 units at $0.83), increasing direct ownership by 15% to 8,449,266 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    4/24/26 8:40:21 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Kosasa Thomas bought $749,999 worth of shares (876,136 units at $0.86), increasing direct ownership by 6% to 16,661,327 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    4/24/26 8:40:19 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    SEC Filings

    View All

    OneMedNet Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - OneMedNet Corp (0001849380) (Filer)

    4/20/26 5:15:33 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 424B3 filed by OneMedNet Corp

    424B3 - OneMedNet Corp (0001849380) (Filer)

    3/31/26 6:07:26 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-K filed by OneMedNet Corp

    10-K - OneMedNet Corp (0001849380) (Filer)

    3/30/26 5:57:13 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OneMedNet Goes Live with 80 Million Patient Journeys and Billions of Records

    MINNEAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), today announced that its OneMedNet iRWD™ Platform, built on Palantir Foundry, is now live and fully operational. This major commercialization milestone delivers searchable access to billions of records across 80 million patient journeys in seconds, transforming how life sciences organizations access and analyze multi-modal clinical data at unprecedented scale and speed. Key Commercial Milestones of iRWD™ Platform: OneMedNet iRWD™ Platform Now Live on Palantir Foundry~70%

    4/22/26 9:00:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet Announces Strong 2025 Financials and Advances AI-Driven iRWD™ powered by Palantir Foundry enabling Conversational Search on Real-Time Medical Data

    MINNEAPOLIS, April 06, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), highlights its 2025 results, with robust revenue growth from the prior year, a strengthened balance sheet, and continued commercial momentum driven by Palantir Foundry enabled conversational search on Real-Time medical data from OneMedNet's rapidly growing network. 2025 Financial Highlights: RWD Revenue Growth: RWD revenue increased 329% year-over-year, rising from $292,000 in 2024 to $1,254,000 in 2025, reflecting strong market demand and increased commercial traction.

    4/6/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI

    MINNEAPOLIS, April 01, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), is pleased to announce that Inka Health, a wholly-owned subsidiary of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a collaboration with OneMedNet Inc., under which Onco-Innovations and Inka Health will have access to OneMedNet's iRWD™ platform— powered by Palantir (PLTR) Foundry— providing it access to U.S. real-world oncology data. The agreement is intended to accelerate development timelines, reduce clinical and re

    4/1/26 8:55:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Kenneth Alleyne Joins OneMedNet Board of Directors

    MINNEAPOLIS, March 03, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet"), the leading Real World Data platform powered by AI-driven de-identification, announces the appointment of Dr. Kenneth Alleyne to its Board of Directors. A board-certified orthopedic surgeon specializing in sports medicine, Dr. Alleyne will assume the role of Chair of the Audit Committee, bringing extensive expertise in healthcare, insurance, investment, and corporate governance to the organization. Dr. Alleyne is the managing partner of HartHaven Partners, a healthcare consulting firm supporting private equity and venture capital firms. He co-founded NextLevel Health Partners and Zing Health

    3/3/25 8:35:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet Announces Exciting New Collaboration with Bayer's AI Innovation Platform to Help Accelerate Healthcare AI Development

    MINNEAPOLIS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet" or the "Company"), a Real-World Data (RWD) platform — has announced its collaboration with Bayer's AI Innovation Platform (AIIP). By joining AIIP, the partnership aims to empower the developer teams of healthcare organizations and startups in building scalable and compliant AI-powered medical imaging software products. "We are thrilled to join forces with Bayer's AI Innovation Platform," said Aaron Green, CEO & President of OneMedNet. "This collaboration allows us to combine our regulatory-grade real-world data platform, which aggregates data from our provider network of over 1,400 healthcare

    12/2/24 8:30:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet appoints new CFO

    MINNEAPOLIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Real World Data (RWD), has announced that Bob Golden has joined the OneMedNet Executive Team as Chief Financial Officer spearheading all aspects of the company's financial and accounting operations while continuing to serve as a member of the Board of Directors. Mr. Golden is a Certified Public Accountant with more than 40 years of experience. Mr. Golden has served as the Managing Partner of Cohen, Bender & Golden LLP since 2015, where he provides consulting, accounting and tax services to middle market businesses and owners. Mr. Golde

    9/10/24 8:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Financials

    Live finance-specific insights

    View All

    $ONMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    OneMedNet Reports 815% Bookings Increase and 4.5X increase in Inbound Demand

    MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the third quarter ended September 30, 2025 and operational highlights. Third Quarter Financial Highlights Bookings:  $1.1M in third quarter 2025 bookings, an 815% increase compared to third quarter of 2024.Private Placements: Successfully completed an additional $0.5M private placement of common stock from an insider, providing further investment towards strategic objectives.Further Improved Balance Sheet: Continuing with its efforts first reported at the end of the second qu

    11/17/25 7:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet Reports 80% Reduction in Debt Enabling Focus On Growth

    MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the second quarter ended June 30, 2025, including its significantly improved balance sheet. Second Quarter and First Half 2025 Financial Highlights Improved Balance Sheet: Due to the combination of debt conversions, vendor repayments, and highly discounted debt settlements, total liabilities have been reduced from $19.7 million as of December 31, 2024, to $6.2 million as of June 30, 2025, a reduction of approximately $13.5 million. Additional discounted debt settl

    8/14/25 7:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by OneMedNet Corp

    SC 13G - OneMedNet Corp (0001849380) (Subject)

    11/12/24 3:35:37 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by OneMedNet Corp

    SC 13G - OneMedNet Corp (0001849380) (Subject)

    10/1/24 5:01:18 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by OneMedNet Corp

    SC 13G - OneMedNet Corp (0001849380) (Subject)

    8/5/24 5:15:39 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care